Paraoxonase (PON)1 Q192R functional genotypes and PON1 Q192R genotype by smoking interactions are risk factors for the metabolic syndrome, but not overweight or obesity

Redox Report

Volumn 19, Issue 6, 2014, Pages 232-241

  Bortolasci, Chiara Cristina ^a   Vargas, Heber Odebrecht ^a   Souza Nogueira, André ^a   Moreira, Estefania Gastaldello ^a   Nunes, Sandra Odebrecht Vargas ^a   Berk, Michael ^b,c   Dodd, Seetal ^b,c   Barbosa, Décio Sabbatini ^a   Maes, Michael ^a,b,d  

^a STATE UNIVERSITY OF LONDRINA   (Brazil)

^b DEAKIN UNIVERSITY   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

Cardiovascular; Depression; HDL cholesterol; Metabolic syndrome; Oxidative stress; Paraoxonase 1

Indexed keywords

ALANINE AMINOTRANSFERASE; ARYLDIALKYLPHOSPHATASE 1; ASPARTATE AMINOTRANSFERASE; CREATININE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; UREA; ANTIOXIDANT; ARYLDIALKYLPHOSPHATASE; PON1 PROTEIN, HUMAN;

ADULT; AFRICAN; ARTICLE; ASIAN; BIPOLAR DISORDER; BODY MASS; CAUCASIAN; DNA POLYMORPHISM; DSM-IV; ENZYME ACTIVITY; ETHNICITY; FEMALE; GENETIC CODE; GENETIC REGULATION; GENOTYPE; HUMAN; IMMUNOMODULATION; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; METABOLIC SYNDROME X; OXIDATIVE STRESS; RISK FACTOR; SMOKING; TOBACCO DEPENDENCE; WAIST CIRCUMFERENCE; ADOLESCENT; CARDIOVASCULAR DISEASE; CHEMISTRY; DEPRESSION; GENETICS; HETEROZYGOTE; HYDROLYSIS; MIDDLE AGED; OBESITY; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIOXIDANTS; ARYLDIALKYLPHOSPHATASE; BIPOLAR DISORDER; BODY MASS INDEX; CARDIOVASCULAR DISEASES; DEPRESSION; FEMALE; GENOTYPE; HETEROZYGOTE; HUMANS; HYDROLYSIS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; OVERWEIGHT; OXIDATIVE STRESS; RISK FACTORS; SMOKING; YOUNG ADULT;

EID: 84901481559     PISSN: 13510002     EISSN: 17432928     Source Type: Journal    
DOI: 10.1179/1351000214Y.0000000093     Document Type: Article

References (63)

1. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002; 288: 2709-16.
2. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120(16): 1640-5.
3. Pan A, Keum N, Okereke OI, Sun Q, Kivimaki M, Rubin RR, et al. Bidirectional association between depression and metabolic syndrome: a systematic review and meta-analysis of epidemiological studies. Diabetes Care 2012; 35(5): 1171-80.
4. Grundy SM. Metabolic syndrome: connecting and reconciling cardiovascular and diabetes worlds. J Am Coll Cardiol 2006; 47: 1093-100.
5. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome-a new worldwide definition. Lancet 2005; 366(9491): 1059-62.
6. Kip KE, Marroquin OC, Kelley DE, Johnson BD, Kelsey SF, Shaw LJ, et al. Clinical importance of obesity versus the metabolic syndrome in cardiovascular risk in women: a report from the Women's Ischemia Syndrome Evaluation (WISE) study. Circulation 2004; 109(6): 706-13.
7. He Y, Jiang B, Wang J, Feng K, Chang Q, Zhu S, et al. BMI versus the metabolic syndrome in relation to cardiovascular risk in elderly Chinese individuals. Diabetes Care 2007; 30(8): 2128-34.
8. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005; 365: 1415-28.
9. Unger RH, Clark GO, Scherer PE, Orci L. Lipid homeostasis, lipotoxicity and the metabolic syndrome. Biochim Biophys Acta 2010; 1801: 209-14.
10. Bryan S, Baregzay B, Spicer D, Singal PK, Khaper N. Redoxinflammatory synergy in the metabolic syndrome. Can J Physiol Pharmacol 2013; 91(1): 22-30.
11. Venturini D, Simão AN, Scripes NA, Bahls LD, Melo PA, Belinetti FM, et al. Evaluation of oxidative stress in overweight subjects with or without metabolic syndrome. Obesity (Silver Spring) 2012; 20(12): 2361-6.
12. Litvinov D, Mahini H, Garelnabi M. Antioxidant and antiinflammatory role of paraoxonase 1: implication in arteriosclerosis diseases. N Am J Med Sci 2012; 4(11): 523-32.
13. Razavi AE, Ani M, Pourfarzam M, Naderi GA. Associations between high density lipoprotein mean particle size and serum paraoxonase-1 activity. J Res Med Sci 2012; 17(11): 1020-6.
14. Viram M, RosenblatM, Bisgaier CL, Newton RS, Primo-Parmo SL, La Du BN. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Invest 1998; 101(8): 1581-90.
15. Furlong CE, Suzuki SM, Stevens RC, Marsillach J, Richter RJ, Jarvik GP, et al. Human PON1, a biomarker of risk of disease and exposure. Chem Biol Interact 2010; 187(1-3): 355-61.
16. Martinelli N, Consoli L, Girelli D, Grison E, Corrocher R, Olivieri O. Paraoxonases: ancient substrate hunters and their evolving role in ischemic heart disease. Adv Clin Chem 2013; 59: 65-100.
17. Ferré N, Feliu A, García-Heredia A, Marsillach J, París N, Zaragoza-Jordana M, et al. Impaired paraoxonase-1 status in obese children. Relationships with insulin resistance and metabolic syndrome. Clin Biochem 2013; 46(18): 1830-6.
18. Sentí M, Tomás M, Fitó M, Weinbrenner T, Covas MI, Sala J, et al. Antioxidant paraoxonase 1 activity in the metabolic syndrome. J Clin Endocrinol Metab 2003; 88(11): 5422-6.
19. Liang KW, Lee WJ, Lee IT, Lee WL, Lin SY, Hsu SL, et al. Persistent elevation of paraoxonase-1 specific enzyme activity after weight reduction in obese non-diabetic men with metabolic syndrome. Clin Chim Acta 2011; 412(19-20): 1835-41.
20. Kappelle PJ, Bijzet J, Hazenberg BP, Dullaart RP. Lower serum paraoxonase-1 activity is related to higher serum amyloid a levels in metabolic syndrome. Arch Med Res 2011; 42(3): 219-25.
21. Martinelli N, Micaglio R, Consoli L, Guarini P, Grison E, Pizzolo F, et al. Low levels of serum paraoxonase activities are characteristic of metabolic syndrome and may influence the metabolic-syndrome-related risk of coronary artery disease. Exp Diabetes Res 2012: 231502. doi: 10. 1155/2012/231502. [Epub 2011 Sep 22]. PubMed PMID: 21960992; PubMed Central PMCID: PMC3179885.
22. Tabak O, Gelişgen R, Cicekçi H, Senateş E, Erdenen F, Müderrisoğlu C, et al. Circulating levels of adiponectin, orexin-A, ghrelin and the antioxidant paraoxonase-1 in metabolic syndrome. Minerva Med 2012; 103(4): 323-9.
23. Vávrová L, Kodydková J, Zeman M, Dušejovská M, Macášek J, Staňková B, et al. Altered activities of antioxidant enzymes in patients with metabolic syndrome. Obes Facts 2013; 6(1): 39-47.
24. Liu ME, Liao YC, Lin RT, Wang YS, Hsi E, Lin HF, et al. A functional polymorphism of PON1 interferes with microRNA binding to increase the risk of ischemic stroke and carotid atherosclerosis. Atherosclerosis 2013; 228(1): 161-7.
25. Mackness M, Mackness B. Targeting paraoxonase-1 in atherosclerosis. Expert Opin Ther Targets 2013; 17(7): 829-37.
26. Kordi-Tamandani DM, Hashemi M, Sharifi N, Kaykhaei MA, Torkamanzehi A. Association between paraoxonase-1 gene polymorphisms and risk of metabolic syndrome. Mol Biol Rep 2012; 39(2): 937-43.
27. Rabaeus M, Salen P, de Lorgeril M. Is it smoking or related lifestyle variables that increase metabolic syndrome risk? BMC Med 2013; 11(1): 196.
28. Sun K, Liu J, Ning G. Active smoking and risk of metabolic syndrome: a meta-analysis of prospective studies. PLoS ONE 2012; 7(10): e47791.
29. Slagter SN, Vliet-Ostaptchouk JV, Vonk JM, Boezen HM, Dullaart RP, Kobold AC, et al. Associations between smoking, components of metabolic syndrome and lipoprotein particle size. BMC Med 2013; 11: 195.
30. Nunes SO, Vargas HO, Prado E, Barbosa DS, de Melo LP, Moylan S, et al. The shared role of oxidative stress and inflammation in major depressive disorder and nicotine dependence. Neurosci Biobehav Rev 2013; 37(8): 1336-45.
31. Boemi M, Sirolla C, Testa R, Cenerelli S, Fumelli P, James RW. Smoking is associated with reduced serum levels of the antioxidant enzyme, paraoxonase, in Type 2 diabetic patients. Diabet Med 2004; 21(5): 423-7.
32. Salvi V, Albert U, Chiarle A, Soreca I, Bogetto F, Maina G. Metabolic syndrome in Italian patients with bipolar disorder. Gen Hosp Psychiatry 2008; 30(4): 318-23.
33. Foley DL, Morley KI, Madden PA, Heath AC, Whitfield JB, Martin NG. Major depression and the metabolic syndrome. Twin Res Hum Genet 2010; 13(4): 347-58.
34. Maes M, Kubera M, Obuchowiczwa E, Goehler L, Brzeszcz J. Depression's multiple comorbidities explained by (neuro)inflammatory and oxidative & nitrosative stress pathways. Neuro Endocrinol Lett 2011; 32(1): 7-24.
35. Jacka FN, Ystrom E, Brantsaeter AL, Karevold E, Roth C, Haugen M, et al. Maternal and early postnatal nutrition and mental health of offspring by age 5 years: a prospective cohort study. J Am Acad Child Adolesc Psychiatry 2013; 52(10): 1038-47.
36. Moylan S, Jacka FN, Pasco JA, Berk M. How cigarette smoking may increase the risk of anxiety symptoms and anxiety disorders: a critical review of biological pathways. Brain Behav 2013; 3(3): 302-26.
37. Moylan S, Eyre HA, Maes M, Baune BT, Jacka FN, Berk M. Exercising the worry away: how inflammation, oxidative and nitrogen stress mediates the beneficial effect of physical activity on anxiety disorder symptoms and behaviours. Neurosci Biobehav Rev 2013; 37(4): 573-84.
38. Berk M, Jacka F. Preventive strategies in depression: gathering evidence for risk factors and potential interventions. Br J Psychiatry 2012; 201(5): 339-41.
39. Maes M, Smith R, Christophe A, Vandoolaeghe E, Van Gastel A, Neels H, et al. Lower serum high-density lipoprotein cholesterol (HDL-C) in major depression and in depressed men with serious suicidal attempts: relationship with immune-inflammatory markers. Acta Psychiatr Scand 1997; 95(3): 212-21.
40. Rabe-Jabłonśka J, Poprawska I. Levels of serum total cholesterol and LDL-cholesterol in patients with major depression in acute period and remission. Med Sci Mon 2000; 6: 539-47.
41. Lasser K, Boyd JW, Woolhandler S, Himmelstein DU, McCormick D, Bor DH. Smoking and mental illness: a population-based prevalence study. JAMA 2000; 284(20): 2606-10.
42. Bortolasci CC, Vargas HO, Souza-Nogueira A, Barbosa DS, Moreira EG, Vargas Nunes SO, et al. Lowered plasma paraoxonase (PON)1 activity is a trait marker of major depression and PON1 Q192R gene polymorphism-smoking interactions differentially predict the odds of major depression and bipolar disorder. J Affect Disord 2014; 159: 23-30.
43. Lear SA, James PT, Ko GT, Kumanyika S. Appropriateness of waist circumference and waist-to-hip ratio cutoffs for different ethnic groups. Eur J Clin Nutr 2010; 64: 42-61.
44. Del-Ben CM, Vilela JAA, de S Crippa JA, Hallak JEC, Labate CM, Zuardi AW. Confiabilidade da 'Entrevista Clínica Estruturada para o D. S. M.-IV'-versão clínica traduzida para o português. Rev Bras Psiquiatr 2001; 23(3): 156-9.
45. Moreno RA, Moreno DH. Hamilton andMontgomery & Asberg depression rating scales. Rev Bras Psiquiatr 1998; 25: 262-72.
46. Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO. The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. Br J Addict 1991; 86(9): 1119-27.
47. Richter RJ, Jarvik GP, Furlong CE. Determination of paraoxonase 1. status without the use of toxic organophosphate substrates. Circ Cardiovasc Genet 2008; 1: 147-52.
48. Baum L, Ng HK, Woo KS, Tomlinson B, Rainer TH, Chen X, et al. Paraoxonase 1 gene Q192R polymorphism affects stroke and myocardial infarction risk. Clin Biochem 2006; 39(3): 191-5.
49. Mahrooz A, Gohari G, Hashemi MB, Zargari M, Musavi H, Abedini M, et al. R-carrying genotypes of serum paraoxonase (PON1) 192 polymorphism and higher activity ratio are related to susceptibility against ischemic stroke. Mol Biol Rep 2012; 39(12): 11177-85.
50. Gupta N, Singh S, Maturu VN, Sharma YP, Gill KD. Paraoxonase 1 (PON1) polymorphisms, haplotypes and activity in predicting cad risk in North-West Indian Punjabis. PLoS ONE 2011; 6(5): e17805.
51. Vaisi-Raygani A, Ghaneialvar H, Rahimi Z, Tavilani H, Pourmotabbed T, Shakiba E, et al. Paraoxonase Arg 192 allele is an independent risk factor for three-vessel stenosis of coronary artery disease. Mol Biol Rep 2011; 38(8): 5421-8.
52. Bhaskar S, Ganesan M, Chandak GR, Mani R, Idris MM, Khaja N, et al. Association of PON1 and APOA5 gene polymorphisms in a cohort of Indian patients having coronary artery disease with and without type 2 diabetes. Genet Test Mol Biomarkers 2011; 15(7-8): 507-12.
53. Park KW, Park JJ, Kang J, Jeon KH, Kang SH, Han JK, et al. Paraoxonase 1 gene polymorphism does not affect clopidogrel response variability but is associated with clinical outcome after PCI. PLoS ONE 2013; 8(2): e52779.
54. Bhattacharyya T, Nicholls SJ, Topol EJ, Zhang R, Yang X, Schmitt D, et al. Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA 2008; 299(11): 1265-76.
55. Richter RJ, Jarvik GP, Furlong CE. Paraoxonase 1 status as a risk factor for disease or exposure. Adv Exp Med Biol 2010; 660: 29-35.
56. Draganov DI, Teiber JF, Speelman A, Osawa Y, Sunahara R, La Du BN. Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities. J Lipid Res 2005; 46(6): 1239-47.
57. Parra S, Marsillach J, Aragonès G, Rull A, Beltrán-Debón R, Alonso-Villaverde C, et al. Methodological constraints in interpreting serum paraoxonase-1 activity measurements: an example from a study in HIV-infected patients. Lipids Health Dis 2010; 9: 32.
58. Sentí M, Aubó C, Tomás M. Differential effects of smoking on myocardial infarction risk according to the Gln/Arg 192 variants of the human paraoxonase gene. Metabolism 2000; 49(5): 557-9.
59. Robertson KS, Hawe E, Miller GJ, Talmud PJ, Humphries SE. Northwick Park Heart Study II. Human paraoxonase gene cluster polymorphisms as predictors of coronary heart disease risk in the prospective Northwick Park Heart Study II. Biochim Biophys Acta 2003; 1639(3): 203-12.
60. Rejeb J, Omezzine A, Rebhi L, Boumaiza I, Mabrouk H, Rhif H, et al. Association of PON1 and PON2 polymorphisms with PON1 activity and significant coronary stenosis in a Tunisian population. Biochem Genet 2013; 51(1-2): 76-91.
61. Mezuk B, Eaton WW, Albrecht S, Golden SH. Depression and type 2 diabetes over the lifespan: a meta-analysis. Diabetes Care 2008; 31(12): 2383-90.
62. Luppino FS, de Wit LM, Bouvy PF, Stijnen T, Cuijpers P, Penninx BW, et al. Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies. Arch Gen Psychiatry 2010; 67(3): 220-9.
63. Sullivan PF. Spurious genetic associations. Biol Psychiatry 2007; 61(10): 1121-6.